Biomarkers of asthma and allergic airway diseases
Annals of Allergy, Asthma & Immunology
November 2015 Volume 115, Issue 5, Pages 335-340 CME Review
Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.
Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for ContinuingMedical Education (ACCME) to provide continuing medical education for physicians.
Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximumof 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Planning Committee Members:
Anne M. Fitzpatrick, PhD (Author)
Mitchell H. Grayson, MD (CME Series Editor, Deputy Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief
Physicians involved in providing patient care in the field of allergy/asthma/immunology
At the conclusion of this activity, participants should be able to:
Describe key features of existing and emerging biomarkers of asthma and allergic airway disease
Identify challenges related to the use of biomarkers in the clinical setting
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance